[Antiphospholipid syndrome and pregnancy]

Area of Science:

• Reproductive Medicine
• Immunology
• Obstetrics

Background:

• Antiphospholipid syndrome (APS) is characterized by antiphospholipid antibodies, leading to thrombosis and/or obstetric morbidity.
• Obstetric complications in APS include recurrent early pregnancy loss, stillbirth, preeclampsia, and fetal growth restriction.
• Current treatments involving aspirin and low-molecular-weight heparin improve outcomes but do not eliminate all pregnancy complications.

Purpose of the Study:

• To highlight the persistent challenges in managing pregnancy in women with Antiphospholipid Syndrome.
• To emphasize the need for specialized monitoring and adherence to international standards for high-risk pregnancies affected by APS.

Main Methods:

• Review of current understanding of Antiphospholipid Syndrome and its obstetric manifestations.
• Analysis of the efficacy of existing treatment protocols for APS during pregnancy.
• Emphasis on clinical management guidelines for high-risk pregnancies.

Main Results:

• Despite established treatments, approximately 30% of women with APS experience pregnancy complications.
• Current therapies have improved but not fully resolved adverse pregnancy outcomes in APS patients.
• Women with APS represent a high-risk obstetric population.

Conclusions:

• Pregnancy in women with Antiphospholipid Syndrome remains high-risk.
• Specialized monitoring in dedicated centers is crucial for managing APS pregnancies.
• Adherence to international standards is recommended for optimal care and improved outcomes.